Lactocore is in the early preclinical stage of developing peptide-based therapeutics for a range of depression and anxiety disorders, including post-traumatic stress disorder (PTSD), bipolar disorder, and treatment-resistant depression (TRD). Through a proprietary processing of whey and casein from bovine milk, Lactocore identified a heretofore unknown family of biologically active peptides. The company is using an approach of rational drug design against carefully selected CNS (central nervous system) targets, ensuring highly specific and efficient peptide drug candidates. For more information on the science, research, and development behind Lactocore, visit our website.
Visit Lactocore Website